Bio101

BIO101：Our candidate is an oral small molecule with blockbuster potential
with best-in-class potential targeting the root causes of muscle atrophy

BIO101：Our candidate is an oral small molecule with best-in-class potential, targeting the root causes of muscle atrophy

First-in-class molecule:

  • Validated mechanism of action
  • Activates the MAS receptor (the protective branch of the renin-angiotensin system)
  • Regulates metabolism in smooth, cardiac and skeletal muscle

Favorable safety profile:

  • More than 275 patients have been treated with BIO101 in clinical trials
  • No major adverse events observed

Convenient administration:

  • API produced at industrial scale
  • Advanced CMC (Chemistry, Manufacturing and Controls)
  • Oral capsule suitable for chronic patients

A focused R&D program,dedicated to improving mobility

Indication

Program

Discovery

Lead Optimization

IND Filing Support

Phase I Clinical Trial

Phase II Clinical Trial

Phase III Clinical Trial

Registration

Sarcopenia

SARA

Obesity

OBA

Indication

Program

Discovery

Lead Compound
Optimization

IND Filing Support

Phase I Clinical Trial

Phase II Clinical Trial

Phase III Clinical Trial

Registration

Sarcopenia

SARA

Obesity

OBA

Program

Discovery

Lead Optimization

IND Filing Support

Phase I Clinical Trial

Phase II Clinical Trial

Phase III Clinical Trial

Registration

Sarcopenia

SARA

Obesity

OBA